Arcturus Therapeutics Holdings Inc.
ARCT
$8.25
-$0.39-4.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -71.36% | -58.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -71.36% | -58.04% | |||
| Cost of Revenue | -12.05% | 5.21% | |||
| Gross Profit | -12.65% | -182.63% | |||
| SG&A Expenses | -32.52% | 34.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.51% | 14.38% | |||
| Operating Income | 7.59% | -89.60% | |||
| Income Before Tax | 7.29% | -116.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.27% | -116.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.27% | -116.23% | |||
| EBIT | 7.59% | -89.60% | |||
| EBITDA | 7.68% | -94.46% | |||
| EPS Basic | 8.28% | -109.14% | |||
| Normalized Basic EPS | 8.29% | -109.19% | |||
| EPS Diluted | 8.28% | -109.14% | |||
| Normalized Diluted EPS | 8.29% | -109.19% | |||
| Average Basic Shares Outstanding | 1.10% | 3.40% | |||
| Average Diluted Shares Outstanding | 1.10% | 3.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||